Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways

Immunological Reviews

Volumn 223, Issue 1, 2008, Pages 186-201

  Ware, Carl F ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Autoimmune disease; Cytokines; T cells; TNF superfamily

Indexed keywords

B AND T LYMPHOCYTE ATTENUATOR; CD134 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECOY RECEPTOR 3; HERPESVIRUS ENTRY MEDIATOR; IMMUNOGLOBULIN; INHIBITOR PROTEIN; LYMPHOTOXIN; LYMPHOTOXIN BETA; LYMPHOTOXIN BETA RECEPTOR; PROTEIN LIGHT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BINDING SITE; CELL PROLIFERATION; DENDRITIC CELL; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFECTION; INFLAMMATION; LYMPHOID TISSUE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNE DISEASES; DENDRITIC CELLS; FEEDBACK, BIOCHEMICAL; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOTOXIN ALPHA1, BETA2 HETEROTRIMER; LYMPHOTOXIN BETA RECEPTOR; MICE; RECEPTOR CROSS-TALK; RECEPTORS, IMMUNOLOGIC; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 47249148425     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00629.x     Document Type: Review

References (141)

1. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002 3 : 611 618.
2. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002 2 : 116 126.
3. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005 23 : 515 548.
4. Watanabe N, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003 4 : 670 679.
5. Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol 2004 172 : 5931 5939.
6. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001 104 : 487 501.
7. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003 3 : 609 620.
8. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005 23 : 23 68.
9. Gavrieli M, Sedy J, Nelson CA, Murphy KM. BTLA and HVEM cross talk regulates inhibition and costimulation. Adv Immunol 2006 92 : 157 185.
10. Vonderheide RH, June CH. A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. Immunol Res 2003 27 : 341 356.
11. Appleman LJ, Boussiotis VA. T cell anergy and costimulation. Immunol Rev 2003 192 : 161 180.
12. Saito T, Yamasaki S. Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors. Immunol Rev 2003 192 : 143 160.
13. Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005 105 : 13 21.
14. Subudhi SK, Alegre ML, Fu YX. The balance of immune responses: costimulation verse coinhibition. J Mol Med 2005 83 : 193 202.
15. Granger SW, Ware CF. Commentary: turning on LIGHT. J Clin Invest 2001 108 : 1741 1742.
16. So T, Lee SW, Croft M. Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int J Hematol 2006 83 : 1 11.
17. Ware CF. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005 23 : 787 819.
18. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995 377 : 348 351.
19. Chaplin D, Fu YX. Cytokine regulation of secondary lymphoid organ development. Curr Opin Immunol 1998 10 : 289 297.
20. Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 2003 3 : 642 655.
21. Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006 7 : 344 353.
22. Mauri DN, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998 8 : 21 30.
23. Schneider K, Potter KG, Ware CF. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004 202 : 49 66.
24. Montgomery RI, Warner MS, Lum B, Spear PG. Herpes simplex virus 1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996 87 : 427 436.
25. Murphy KM, Nelson CA, Sedy JR. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol 2006 6 : 671 681.
26. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999 274 : 13733 13736.
27. Force WR, et al. Mouse lymphotoxin-β receptor. Molecular genetics, ligand binding, and expression. J Immunol 1996 155 : 5280 5288.
28. Browning JL, French LE. Visualization of lymphotoxin-beta and lymphotoxin-beta receptor expression in mouse embryos. J Immunol 2002 168 : 5079 5087.
29. Tamada K, et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000 164 : 4105 4110.
30. Edwards AD, Chaussabel D, Tomlinson S, Schulz O, Sher A, Reis e Sousa C. Relationships among murine CD11c(high) dendritic cell subsets as revealed by baseline gene expression patterns. J Immunol 2003 171 : 47 60.
31. Taylor RT, Lugering A, Newell KA, Williams IR. Intestinal cryptopatch formation in mice requires lymphotoxin alpha and the lymphotoxin beta receptor. J Immunol 2004 173 : 7183 7189.
32. Meier D, et al. Ectopic lymphoid-organ development occurs through Interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity 2007 26 : 643 654.
33. Cyster JG, et al. Follicular stromal cells and lymphocyte homing to follicles. Immunol Rev 2000 176 : 181 193.
34. Scheu S, Alferink J, Potzel T, Barchet W, Kalinke U, Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 2002 195 : 1613 1624.
35. Cohavy O, Zhou J, Ware CF, Targan SR. LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling. J Immunol 2005 174 : 646 653.
36. Sedy JR, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005 6 : 90 98.
37. Hurchla MA, Sedy JR, Gavrielli M, Drake CG, Murphy TL, Murphy KM. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells. J Immunol 2005 174 : 3377 3385.
38. Peter ME, et al. The CD95 receptor: apoptosis revisited. Cell 2007 129 : 447 450.
39. Li C, et al. Structurally distinct recognition motifs in lymphotoxin-beta receptor and CD40 for tumor necrosis factor receptor-associated factor (TRAF)-mediated signaling. J Biol Chem 2003 278 : 50523 50529.
40. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003 14 : 193 209.
41. Li ZW, Rickert RC, Karin M. Genetic dissection of antigen receptor induced-NF-kappaB activation. Mol Immunol 2004 41 : 701 714.
42. Ruland J, Mak TW. From antigen to activation: specific signal transduction pathways linking antigen receptors to NF-kappaB. Semin Immunol 2003 15 : 177 183.
43. Green DR. Death and NF-kappaB in T cell activation: life at the edge. Mol Cell 2003 11 : 551 552.
44. Dejardin E, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002 17 : 525 535.
45. Pineda G, Ea CK, Chen ZJ. Ubiquitination and TRAF signaling. Adv Exp Med Biol 2007 597 : 80 92.
46. Oganesyan G, et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 2006 439 : 208 211.
47. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007 8 : 49 62.
48. Rooney IA, et al. The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 2000 275 : 14307 14315.
49. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002 27 : 19 26.
50. Bossen C, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 2006 281 : 13964 13971.
51. Holler N, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003 23 : 1428 1440.
52. Banner DW, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993 73 : 431 445.
53. Compaan DM, Hymowitz SG. The crystal structure of the costimulatory OX40-OX40L complex. Structure 2006 14 : 1321 1330.
54. Hymowitz SG, et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999 4 : 563 571.
55. Hymowitz SG, et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem 2005 280 : 7218 7227.
56. Cachero TG, et al. Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). Biochemistry 2006 45 : 2006 2013.
57. Eldredge J, et al. Stoichiometry of LTbetaR binding to LIGHT. Biochemistry 2006 45 : 10117 10128.
58. Ware CF, VanArsdale TL, Crowe PD, Browning JL. The ligands and receptors of the lymphotoxin system. In : Griffiths GM, Tschopp J, eds. Pathways for Cytolysis. Basel : Springer-Verlag, 1995 : 175 218.
59. Williams-Abbott L, Walter BN, Cheung TC, Goh CR, Porter AG, Ware CF. The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha1beta2 heterotrimeric ligand. J Biol Chem 1997 272 : 19451 19456.
60. Black RA, et al. Substrate specificity and inducibility of TACE (tumour necrosis factor alpha-converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity. Biochem Soc Symp 2003 70 : 39 52.
61. Granger SW, Butrovich KD, Houshmand P, Edwards WR, Ware CF. Genomic characterization of LIGHT reveals linkage to an immune response locus on chromosome 19p13.3 and distinct isoforms generated by alternate splicing or proteolysis. J Immunol 2001 167 : 5122 5128.
62. Chen J, Zhang L, Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods 2004 285 : 63 70.
63. Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG. Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J Biol Chem 2005 280 : 39553 39561.
64. Garapati VP, Lefranc MP. IMGT Colliers de Perles and IgSF domain standardization for T cell costimulatory activatory (CD28, ICOS) and inhibitory (CTLA4, PDCD1 and BTLA) receptors. Dev Comp Immunol 2007 31 : 1050 1072.
65. Keir ME, Sharpe AH. The B7/CD28 costimulatory family in autoimmunity. Immunol Rev 2005 204 : 128 143.
66. Chemnitz JM, Lanfranco AR, Braunstein I, Riley JL. B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. J Immunol 2006 176 : 6603 6614.
67. Wu TH, Zhen Y, Zeng C, Yi HF, Zhao Y. B and T lymphocyte attenuator interacts with CD3zeta and inhibits tyrosine phosphorylation of TCRzeta complex during T-cell activation. Immunol Cell Biol 2007 85 : 590 595.
68. Gonzalez LC, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci USA 2005 102 : 1116 1121.
69. Cheung TC, et al. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc Natl Acad Sci USA 2005 102 : 13218 13223.
70. Nelson CA, et al. Structural determinants of herpesvirus entry mediator recognition by murine B and T lymphocyte attenuator. J Immunol 2008 180 : 940 947.
71. Croft M. The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA. Trends Immunol 2005 26 : 292 294.
72. Watts TH, Gommerman JL. The LIGHT and DARC sides of herpesvirus entry mediator. Proc Natl Acad Sci USA 2005 102 : 13365 13366.
73. Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits activation of human CD4(+) T cells through interaction with herpesvirus entry mediator. Nat Immunol 2008 9 : 176 185.
74. Benedict C, et al. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J Immunol 1999 162 : 6967 6970.
75. Spear PG. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 2004 6 : 401 410.
76. Spear PG, Manoj S, Yoon M, Jogger CR, Zago A, Myscofski D. Different receptors binding to distinct interfaces on herpes simplex virus gD can trigger events leading to cell fusion and viral entry. Virology 2006 344 : 17 24.
77. Lurain NS, et al. Human cytomegalovirus UL144 open reading frame: sequence hypervariability in low-passage clinical isolates. J Virol 1999 73 : 10040 10050.
78. Kinkade A, Ware CF. The DARC conspiracy - virus invasion tactics. Trends Immunol 2006 27 : 362 367.
79. Kwon BS, et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem 1997 272 : 14272 14276.
80. Harrop JA, et al. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J Immunol 1998 161 : 1786 1794.
81. Ye Q, et al. Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival. J Exp Med 2002 195 : 795 800.
82. Shaikh R, et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation and tissue destruction. J Immunol 2001 167 : 6330 6337.
83. Wang J, et al. The regulation of T cell homeostasis and autoimmunity by T cell derived LIGHT. J Clin Invest 2001 108 : 1771 1780.
84. Tamada K, et al. Cutting Edge: selective impairment of CD8(+) T Cell function in mice lacking the TNF superfamily member LIGHT. J Immunol 2002 168 : 4832 4835.
85. Tamada K, et al. Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 2002 109 : 549 557.
86. Wan X, et al. A TNF family member LIGHT transduces costimulatory signals into human T cells. J Immunol 2002 169 : 6813 6821.
87. Hurchla MA, Sedy JR, Murphy KM. Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation. J Immunol 2007 178 : 6073 6082.
88. Lin SC, Kuo CC, Chan CH. Association of a BTLA gene polymorphism with the risk of rheumatoid arthritis. J Biomed Sci 2006 13 : 853 860.
89. Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun 2003 312 : 1236 1243.
90. Deppong C, et al. Cutting edge: B and T lymphocyte attenuator and programmed death receptor-1 inhibitory receptors are required for termination of acute allergic airway inflammation. J Immunol 2006 176 : 3909 3913.
91. Banchereau J, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000 18 : 767 811.
92. Asselin-Paturel C, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001 2 : 1144 1150.
93. Martin P, et al. Characterization of a new subpopulation of mouse CD8alpha+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 2002 100 : 383 390.
94. Maldonado-Lopez R, et al. CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999 189 : 587 592.
95. Maldonado-Lopez R, Moser M. Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin Immunol 2001 13 : 275 282.
96. Leenen PJ, et al. Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J Immunol 1998 160 : 2166 2173.
97. Kabashima K, Banks TA, Ansel KM, Lu TT, Ware CF, Cyster JG. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 2005 22 : 439 450.
98. Abe K, et al. Distinct contributions of TNF and LT cytokines to the development of dendritic cells in vitro and their recruitment in vivo. Blood 2003 101 : 1477 1483.
99. De Trez C, et al. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J Immunol 2008 180 : 238 248.
100. Wu L, D'Amico A, Winkel KD, Suter M, Lo D, Shortman K. RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity 1998 9 : 839 847.
101. Krieg C, Boyman O, Fu YX, Kaye J. B and T lymphocyte attenuator regulates CD8(+) T cell-intrinsic homeostasis and memory cell generation. Nat Immunol 2007 8 : 162 171.
102. Xu Y, et al. Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. Blood 2007 109 : 4097 4104.
103. Summers-DeLuca LE, et al. Expression of lymphotoxin-alphabeta on antigen-specific T cells is required for DC function. J Exp Med 2007 204 : 1071 1081.
104. Wang Y, et al. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest 2005 115 : 711 717.
105. Schneider K, et al. Lymphotoxin-mediated crosstalk between B-cells and splenic stroma promotes the initial type I interferon response to cytomegalovirus. Cell Host Microbe 2008 3 : 67 76.
106. Benedict CA, De Trez C, Schneider K, Ha S, Patterson G, Ware CF. Specific remodeling of splenic architecture by cytomegalovirus. PLoS Pathog 2006 2 : e16.
107. Benedict CA, et al. Lymphotoxins and cytomegalovirus cooperatively induce interferon-b, establishing host-virus détente. Immunity 2001 15 : 617 626.
108. Banks TA, et al. A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J Immunol 2005 174 : 7217 7225.
109. Banks TA, Rickert S, Ware CF. Restoring immune defenses via lymphotoxin signaling: lessons from cytomegalovirus. Immunol Res 2006 34 : 243 254.
110. Fava RA, et al. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 2003 171 : 115 126.
111. Gommerman JL, et al. A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT. J Clin Invest 2003 112 : 755 767.
112. Schwarz BT, et al. LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology 2007 132 : 2383 2394.
113. An MM, et al. Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/HVEM signaling. Pharmacol Res 2005 52 : 234 244.
114. An MM, et al. Lymphtoxin beta receptor-Ig protects from T-cell-mediated liver injury in mice through Blocking LIGHT/HVEM signaling. Biol Pharm Bull 2006 29 : 2025 2030.
115. Anand S, et al. Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. J Clin Invest 2006 116 : 1045 1051.
116. Cohavy O, Zhou J, Granger SW, Ware CF, Targan SR. LIGHT expression by mucosal T cells may regulate IFN-gamma expression in the intestine. J Immunol 2004 173 : 251 258.
117. Truong W, et al. Negative and positive co-signaling with anti-BTLA (PJ196) and CTLA4Ig prolongs islet allograft survival. Transplantation 2007 84 : 1368 1372.
118. Truong W, Hancock WW, Anderson CC, Merani S, Shapiro AM. Coinhibitory T-cell signaling in islet allograft rejection and tolerance. Cell Transplant 2006 15 : 105 119.
119. Yu P, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004 5 : 141 149.
120. Tamada K, et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med 2000 6 : 283 289.
121. Lo JC, et al. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 2007 316 : 285 288.
122. Wang J, et al. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J Immunol 2005 174 : 8173 8182.
123. Fan Z, et al. NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood 2006 107 : 1342 1351.
124. Brown GR, Lee EL, El-Hayek J, Kintner K, Luck C. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease. J Immunol 2005 174 : 4688 4695.
125. Wu Q, Fu YX, Sontheimer RD. Blockade of lymphotoxin signaling inhibits the clinical expression of murine graft-versus-host skin disease. J Immunol 2004 172 : 1630 1636.
126. Plant SR, et al. Lymphotoxin beta receptor (Lt betaR): dual roles in demyelination and remyelination and successful therapeutic intervention using Lt betaR-Ig protein. J Neurosci 2007 27 : 7429 7437.
127. Truong W, et al. Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts. Am J Transplant 2007 7 : 2663 2674.
128. Lee BJ, Santee S, Von Gesjen S, Ware CF, Sarawar SR. Lymphotoxin a -/- mice can clear a productive infection with murine gammaherpevirus-68 (MHV-68) but fail to develop splenomegaly or lymphocytosis. J Virol 2000 74 : 2786 2792.
129. Kumaraguru U, Davis IA, Deshpande S, Tevethia SS, Rouse BT. Lymphotoxin alpha(-/-) mice develop functionally impaired CD8(+) T cell responses and fail to contain virus infection of the central nervous system. J Immunol 2001 166 : 1066 1074.
130. Berger DP, Naniche D, Crowley MT, Koni PA, Flavell RA, Oldstone MB. Lymphotoxin-b-deficient mice show defective antiviral immunity. Virol 1999 260 : 136 147.
131. Suresh M, et al. Role of lymphotoxin alpha in T-cell responses during an acute viral infection. J Virol 2002 76 : 3943 3951.
132. Puglielli MT, et al. Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway. Nat Med 1999 5 : 1370 1374.
133. Lin X, et al. Membrane lymphotoxin is required for resistance to Theiler's virus infection. Int Immunol 2003 15 : 955 962.
134. Lund FE, et al. Lymphotoxin-alpha-deficient mice make delayed, but effective, T and B cell responses to influenza. J Immunol 2002 169 : 5236 5243.
135. Ehlers S, et al. The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J Immunol 2003 170 : 5210 5218.
136. Roach DR, Briscoe H, Saunders B, France MP, Riminton S, Britton WJ. Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. J Exp Med 2001 193 : 239 246.
137. Lucas R, et al. A role for lymphotoxin beta receptor in host defense against Mycobacterium bovis BCG infection. Eur J Immunol 1999 29 : 4002 4010.
138. Wilhelm P, et al. Membrane lymphotoxin contributes to anti-leishmanial immunity by controlling structural integrity of lymphoid organs. Eur J Immunol 2002 32 : 1993 2003.
139. Xu G, et al. LIGHT is critical for IL-12 production by dendritic cells, optimal CD4+ Th1 cell response, and resistance to Leishmania major. J Immunol 2007 179 : 6901 6909.
140. Schluter D, et al. Both lymphotoxin-alpha and TNF are crucial for control of Toxoplasma gondii in the central nervous system. J Immunol 2003 170 : 6172 6182.
141. Engwerda CR, Mynott TL, Sawhney S, De Souza JB, Bickle QD, Kaye PM. Locally up-regulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria. J Exp Med 2002 195 : 1371 1377.